Piscataway, NJ, August 24, 2023–Camber Pharmaceuticals is pleased to announce the addition of Ezetimibe Tablets, USP to its current portfolio.
Ezetimibe Tablets, USP are an inhibitor of intestinal cholesterol (and related phytosterol) absorption indicated as an adjunct to diet to:
- Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin)
- Reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate
- Reduce elevated total-C and LDL-C in patients with homozygous familial hypercholesterolemia (HoFH), in combination with atorvastatin or simvastatin
- Reduce elevated sitosterol and campesterol in patients with homozygous sitosterolemia (phytosterolemia)
Ezetimibe 10 mg Tablets are available in 30 and 90 count bottles.
To find out more about Ezetimibe Tablets, USP please visit www.camberpharma.com.
Camber Pharmaceuticals is a fully integrated pharmaceutical company. Its parent company, Hetero, of Hyderabad, India, is one of the world’s leading API and finished dosage manufacturers. Camber is committed to bringing the highest quality generic pharmaceuticals to consumers, improving quality of life through cost-effective medications.
# # #
If you would like more information about this topic, please contact Megan Little at [email protected]
